Movement Disorders and Its Variants

Abstract

Since the 2000s, Nuclear Medicine has primarily used SPECT with DaTSCAN and PET with [18F]-FDG to explore movement disorders. Recent advances in PET radiotracers, such as LBT 999 for dopamine transporters and tau tracers like flortaucipir for tauopathies, are enhancing diagnostic precision. Other PET tracers target neuroinflammation, synaptic density, cholinergic function, and adenosine A2A receptors. Novel tools like [18F]-ROStrace help detect oxidative stress in neurodegenerative disorders. These developments promise better patient management, reduced examination times, and improved diagnostic accuracy in the exploration of movement disorders pathologies.

Keywords: Dopaminergic; Movement disorders; PET; Tauopathy.